The characterization, current medications, and promising therapeutics targets for premature ejaculation

Summary Premature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated with negative personal and interpersonal psychological outcomes. The pharmacologic treatment of PE includes the use of antidepressants, local anesthetic agents, and phosphodiesterase type 5 inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:Andrology (Oxford) 2015-05, Vol.3 (3), p.424-442
Main Authors: Gur, S., Sikka, S. C.
Format: Article
Language:English
Subjects:
Androgens - metabolism
Anesthetics, Local - therapeutic use
Antidepressants
Antidepressive Agents - therapeutic use
Benzylamines - therapeutic use
dapoxetine
Drug therapy
Ejaculation - physiology
Endocrine System - physiology
Humans
intravaginal ejaculation latency time
Male
Naphthalenes - therapeutic use
pathophysiology
Phosphodiesterase 5 Inhibitors - therapeutic use
premature ejaculation
Premature Ejaculation - drug therapy
Premature Ejaculation - physiopathology
selective serotonin reuptake inhibitors
serotonin
Serotonin Uptake Inhibitors - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Premature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated with negative personal and interpersonal psychological outcomes. The pharmacologic treatment of PE includes the use of antidepressants, local anesthetic agents, and phosphodiesterase type 5 inhibitors. While numerous treatments can control PE, only antidepressants and topical anesthetic creams and sprays have recently been shown to be more effective. This review focuses on the physiology and pharmacology of ejaculation, the pathophysiology of PE and the most effective pharmacological treatment of PE. Pharmacotherapy of PE with off‐label short‐acting selective serotonin reuptake inhibitors (SSRIs) is common, effective, and safe. Dapoxetine, a SSRI with a short half‐life, has been recently evaluated for the treatment of PE by several countries and results are promising. In clinical practice, follow‐up side effects are an important part of the management strategy for PE. The understanding of etiology, pathophysiology, and treatment modalities of PE would be beneficial to clinician in helping patients with this disappointing sexual problem.
ISSN:2047-2919
2047-2927
DOI:10.1111/andr.12032